Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

Yael C. Cohen*, Hila Magen, Noa Lavi, Moshe E. Gatt, Evgeni Chubar, Nethanel Horowitz, Natalia Kreiniz, Tamar Tadmor, Svetlana Trestman, Roy Vitkon, Ory Rouvio, Olga Shvetz, Adir Shaulov, Tomer Ziv-Baran, Irit Avivi

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study'. Together they form a unique fingerprint.

Medicine & Life Sciences